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Abstract
We have developed a structurally-guided scaffold phage display strategy for identification of ligand mimetic bio-
therapeutics. As a proof of concept we used the ligand of integrin avb6, a tumour cell surface receptor and a major new
target for imaging and therapy of many types of solid cancer. NMR structure analysis showed that RGD-helix structures are
optimal for avb6 ligand-interaction, so we designed novel algorithms to generate human single chain fragment variable
(scFv) libraries with synthetic VH-CDR3 encoding RGD-helix hairpins with helices of differing pitch, length and amino acid
composition. Study of the lead scFv clones D25scFv and D34scFv and their corresponding VH-CDR3 derived peptides, D25p
and D34p, demonstrated: specific binding to recombinant and cellular avb6; inhibition of avb6-dependent cell and ligand
adhesion, avb6-dependent cell internalisation; and selective retention by avb6-expressing, but not avb6-negative, human
xenografts. NMR analysis established that both the D25p and D34p retained RGD-helix structures confirming the success of
the algorithm. In conclusion, scFv libraries can be engineered based on ligand structural motifs to increase the likelihood of
developing powerful bio-therapeutics.
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Introduction
The use of combinatorial phage display scFv libraries for
generation of therapeutic antibodies is well established and has
resulted in clinically valuable reagents [1,2]. ScFv libraries are
commonly made from immune or naı̈ve B cells or as synthetic
libraries where antibody variable heavy (VH) and variable light
(VL) gene segments are rearranged in vitro with synthetic
complementarity determining regions (CDRs) coding for random
sequences of varying lengths [3–5]. The use of the phage display
library has been used to develop antibodies for therapeutic
intervention using the above combinatorial libraries. We reasoned
that the use of antibody engineering in combination with ligand
structural studies will result in robust libraries that can lead to
isolation of potent ligand-mimetic bio-therapeutic antibody
candidates.
Since receptor:ligand interactions must be considered as
interacting topographical maps we wondered if it were possible
to generate a target-selective library by incorporating a panel of
specific three-dimensional shapes into the CDR3 of the variable
heavy (VH-CDR3). If such a library used stereochemical shapes
that corresponded to a ligand-binding interface then it would more
likely generate scFv(s) that will block the ligand:receptor interac-
tion than would a conventional random library. To test this
hypothesis we considered a therapeutically relevant target, the
integrin avb6, which represents a novel and important tumour-
selective target that is expressed on the surface of cancer cells. We,
and others, have shown that avb6 promotes cancer cell migration,
invasion and growth in vivo [6–10]. Moreover strong expression of
avb6 correlates with poor prognosis in multiple cancers [11–13]
and thus human therapeutic antibodies to this integrin are likely to
have a significant therapeutic value.
In previous studies we identified the 20mer peptide
A20FMDV2 (N1A2V3P4N5L6R7G8D9L10Q11V12L13A14Q15K16-
1A2V3P4N5L6R7G8D9L10Q11V12L13A14Q15K16V17A18R19T20),
derived from the foot and mouth disease virus VP1 coat protein, as
a highly specific and potent ligand for avb6 [14]. The peptide
included the avb6-binding motif RGDLXXL identified by Kraft
et al (1999) [15]. Using NMR we determined the three-
dimensional structure of A20FMDV2 in 30% TFE: a hairpin
structure with RGD at the tip of the turn followed by a C-terminal
helix [14]. This structural motif has also been observed in
additional avb6-binding peptides (Wagstaff et al, 2012, [14]). In
addition, we have previously probed the role of the helix in
A20FMDV2 through the use of specific D-amino acids to disrupt
helix formation, and found the resulting helix-attenuated peptide
had greatly reduced binding to cells expressing avb6 [14].
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In this study we have used our NMR data to design algorithms
to build phage display human scFv libraries that would retain the
key structural residues that would encode a library of RGD-helix
hairpin structural motifs where the helices could vary in length,
pitch and sequence composition. Our data show that it is possible
to design scFv libraries that include structural motifs within the
VH-CDR3 to provide potent ligand antagonising antibody
candidates that can be developed for cancer therapy.
Results
Library design
Our rationale was to introduce a structural selectivity to a phage
display library where the three-dimensional (3D) avb6 ligand
recognition motif (RGD-helix) was genetically encoded into the
antibody binding pocket at the VH-CDR3. Figure 1A shows the
amino-acid sequence identity and mean NMR solution structure
of A20FMDV2. From these data plus the STD-NMR data [14] we
designed two algorithms to develop VH-CDR3 libraries encoding
a hairpin containing at its turn, an RGD motif, followed by a C-
terminal a-helix (Figure 1B) or a 310-helix (Figure 1C); the helical
wheel map for each library is also shown. The template synthetic
VH-CDR3 was based on the a-helix donor sequence
L8A9R10L11K12R13E14F15N16E17, which is helix 1 from the
Drosophila engrailed homeodomain ((EN-HD) [16]). However in
the library the L8 was changed to A8 in order to prevent formation
of an LXXLL motif. The a-helix template VH-CDR3 algorithm
was: E1P2R3G4D5L6X7X8L9A10A11R12Z13K14R15Z16F17N18E19
Z20L21A22Z23L24Q25E26K27G28I29 where Z and X were random
amino-acid residues introduced into the same quadrant as the
leucine residues of the RGDLXXL motif: at position 13, 16, 20
and 23 in the a-helix based on the helical wheel (3.6 residues per
turn of helix). The EP and the LQEKGI motifs were N- and C-
terminal helix-capping regions, respectively (based on the standard
Schellmann C-cap: Leu-Gln-Glu-Lys-Gly-Ile (LQEKGI) [17]
(Figure 1B). To extend the helix length further, the EN-HD
donor sequence was repeated from positions 21/22 in the library.
To build the 310 helix library we used the E1P2R3G4D5L6
X7X8L9A10A11Z12L13K14Z15E16F17Z18E19N20Z21L22A23Z24L25
Q26E27K28G29I30 template inserting a random amino acid
residue in every third position following the RGDLXXL motif
in the 310 helix (3.0 residues per turn of 310 helix, Figure 1C).
Hence, the random residues automatically provided helices of
different lengths because they included helix stabilising residues,
such as alanine, lysine or arginine or, alternatively, helix
destroying residues such as proline [18] as well as including
residues covering all side chain properties to test the effect of
charge, hydrophobicity and steric interactions.
Library selection and screening for lead candidates
After 3 rounds of alternate panning on immobilised recombi-
nant avb6 and cells expressing avb6, greater than two thirds of
clones bound to recombinant avb6 in ELISA (Figure 2A). Binders
revealed at least 24 unique VH-CDR3 sequences corresponding to
both an a-helix and 310 helix libraries. In flow cytometry
experiments none of the scFv bound to the avb6-negative cells
and many scFv bound well to the avb6-expressing cells. Since we
used pair of cell lines that are isogenic and differ only by avb6 but
endogenously express four other RGD directed integrins a5b1,
avb3, avb5 and avb8 [19,20] these data suggest strongly that the
scFvs exhibited avb6-specific binding (Fig. 2B). However, based
upon a combination of scFv protein expression yields, biochemical
stability (size-exclusion chromatography) and strength of binding
to cellular avb6 (flow cytometry) we focussed our study on 2
different scFvs clones: D25scFv (D25) and D34scFv (D34)
(Figure 2C). VH-CDR3 sequences of both D25 and D34 encoded
a-helix as follows: EPRGDLRTLAAREKRNFNETLARL-
QEKGI and QPRGDLRELAARSEAQLQEKGI, for D25 and
D34, respectively. Clone D34 had mutation from C to G that
resulted in replacement of E to Q in the N-terminal helix-capping
regions. The size-exclusion chromatography profile of the purified
D34scFv showed a main peak eluting at 70 ml, corresponding to
the 30 kDa scFv. For D25scFv we also observed a lower peaks
eluting at 45–60 ml, corresponding to scFv dimers and tetramers,
occasionally seen with some scFv [5] (Figure 2C).
avb6-specific antagonistic efficacy
A dose dependent binding analysis of both D25scFv and
D34scFv and their corresponding VH-CDR3 peptides (D25p and
D34p, respectively) exhibited avb6-specific binding to A375Pb6
cells but not A375Ppuro (Figure 3A and Figure S1). Additionally,
D25scFv, D34scFv, D25p and D34p showed a dose-dependent
inhibition of binding to cellular avb6 of A20FMDV2 peptide
(NAVPNLRGDLQVLAQKVART), a peptide that is 1000-fold
more selective for avb6 over a5b1, avb3, avb5 and avb8 integrins
and binds with high affinity (KD 1.7 nM) to the avb6 integrin [19]
(Figure 3B–C). Moreover, D25scFv, D25p, D34scFv and D34p
exhibited significant concentration-dependent inhibition of avb6-
dependent adhesion of carcinoma cells to immobilised fibronectin
(Figure 3D–E). Inhibition by D25p was significantly stronger than
D34p (p = 0.0156)
avb6-specific internalization
D25scFv and D34scFv exhibited cellular internalisation in
avb6-expressing cells but not in avb6-negative cells. At 0 minutes,
the scFvs were localised at the cell surface (Figure 4A and 4D for
D25scFv and D34scFv, respectively) but after incubation at 37uC
for 45 minutes, they were localised within the cell cytoplasm and
nucleus (Figure 4B and 4E for D25scFv and D34scFv, respective-
ly). Omitting the scFv primary layer and labelling only with anti-
myc and the fluorochrome-labelled secondary antibody showed
very little nuclear staining suggesting the nuclear localisation of the
scFvs was real (Figure 4C and 4F for D25scFv and D34scFv,
respectively). Similarly, biotinylated-D25p and biotinylated-D34p
also underwent cellular internalisation in avb6-expressing cells
(Figure 4H and 4K for D25p and D34p, respectively) but not in
avb6-negative cells (Figure 4I, and 4L for D25p and D34p,
respectively). Efficient internalisation was observed at 30–45 min-
utes (Figure 4H, K for D25p and D34p, respectively) but no
nuclear localisation was observed.
Biotinylated-D25 peptide localises to avb6-expressing
tumours in vivo
When 12.5MBq of [In111]-DTPA-Streptavidin decorated with
biotinylated-D25p was intravenously injected into three mice
bearing both a subcutaneous avb6-positive A375Pb6 tumour and
an avb6-negative A375Ppuro tumour, on opposite shoulders, we
observed a 23% injected dose per gram uptake in the avb6-
positive tumour compared with only 3% for the avb6-negative
tumour at 1 hour post-injection, a ratio of almost 8:1 (Figure 5).
This translated into a very clear discrimination of the avb6-
positive tumour by single-photon emission computed tomography
(SPECT) imaging (Figure 5).
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Structural determination of D25 and D34 peptides by
NMR
We used NMR to solve the solution structures for peptides
D34p and D25p. Figure 6 shows the 3D-rendering model closest
to the mean calculated for each peptide from an ensemble of 20
NMR structures; the associated structural statistical data from
CNS for both peptides is available in Table S1 and NOE and
structural contact information is available in Figures S2, S3, S4.
Both peptides exhibited the RGD-helix motif. D34 which has 22
amino-acids has a shorter helix than peptide D25, which has 29
amino-acids. Helices for both peptides were defined as standard a-
helix with the D34 a-helix running from Leu6-Leu17 and D25 a-
helix running from Leu6-Gln25.
Discussion
CDR grafting, the replacing of complementarity-determining
regions in a mouse antibody with those from a human antibody,
has been used for more than two decades for humanization of
mouse monoclonal antibodies and development of immunother-
apy [20]. CDR grafting of ligands into CDR loops to bind to a
specific receptor was originally reported by Barbas et al in 1993
where they produced semisynthetic human antibodies library that
included RGD motifs followed by random sequences to select for
antibody fragments specific to the integrins avb5, avb3, and
aIIIbb3 [21]. Kogelberg et al inserted 17 residues from
A20FMDV2 into the CDR3 region into an anti-CEA scFv
thereby creating an antibody with avb6-specificity [22]. More
recently, a peptide sequence that bound to an inorganic material
surface, was grafted into the CDR of a camel-type single domain
antibody rearranged with a library of random sequences in
additional CDR. Authors noted a synergistic effect from the
grafted and selected random CDR loops that drastically increased
the affinity for the inorganic target [23]. In this study we have
taken a different approach, namely, grafting a 3-dimensional
geometry based library designed from a ligand:receptor binding
stereochemical interface. To test the model we chose a therapeu-
tically valuable target, the integrin avb6 that we, and others, have
Figure 1. a-helix and 310-helix Library design. A) Amino acid sequence and NMR solution structure of A20FMDV2 with a hairpin structure with
RGD at the tip of the turn followed by a C-terminal helix is shown. B) a-helix algorithm used to design the VH-CDR3 encoding a hairpin containing at
its turn an RGD motif, followed by a C-terminal a-helix. C) 310-helix algorithm used to designed the VH-CDR3 encoding a hairpin containing at its turn
an RGD motif, followed by a C-terminal 310-helix. Amino acid positions that are available for randomisation are highlighted (X and Z shown in blue
and red, respectively).
doi:10.1371/journal.pone.0070452.g001
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reported is associated with poor survival from cancer, presumed to
be because this integrin promotes carcinoma invasion and survival
[6–9]. We had identified previously avb6-binding peptides from
high affinity ligands for avb6 and shown that interrogation of the
peptide structures by various NMR techniques revealed 1) all three
ligands (A20FMDV1, LAP, A20FMDV2) were hairpin-shaped
peptides with RGD at the turn followed by an helix and 2) the
Asp+1 and Asp+4 residues were exposed on the same face of the
helix and appeared to form a hydrophobic binding interface with
the integrin and 3) potency of avb6 inhibition appeared to
correlate with the length of the helix [14,24]. Thus we designed
two algorithms to retain these structural elements while allowing
for variation in amino-acid composition and helix length.
We have used our NMR data to design algorithms that would
retain the key structural residues that would encode a library of
RGD-helix-hairpin structural motifs where the helices would be of
varying lengths and sequence composition. We used the
algorithms to create two structurally-guided scFv libraries that
incorporate either an a- or a 310-helix C-terminal to the
RGDLXXL motif within VH-CDR3.
Screening of 96 clones isolated following three rounds of
biopanning with the combined a-helix and 310-helix libraries
revealed H-CDR3 sequences of both a-type and 310-type,
indicating that both library designs are capable of producing
avb6-binding scFv. The scFv and the VH-CDR3 derived peptides
from the two lead clones, D25scFv, D34scFv, D25p and D34p: 1)
bound only to avb6-expressing cells (A375Pb6) but not to cells that
expressed avb3, avb5, avb8 and a5b1 (A375Ppuro) 2) exhibited
dose-dependent inhibition of the avb6-specific ligand A20FMDV2
binding to cellular avb6 3) inhibited carcinoma cell avb6-
dependent adhesion to fibronectin 4) and were internalised into
cells in an avb6-dependent manner. These characteristics make
these two lead clones excellent candidates for development as
therapeutic antibodies. In advance of this we tested whether the
D25p possessed similar in vivo targeting capabilities that we had
previously shown for A20FMDV2. Data showed that the
radiolabelled D25p selectively located to avb6-expressing tumours
in vivo showing that the structurally designed library could generate
unique compounds with in vivo efficacy and specificity. Our
attempts to radiolabel the D25scFv and D34scFv resulted in loss of
antibody activity so in vivo experiments were not attempted. This
will need to be addressed in future studies where radiolabeling
protocols will need to be modified. Hence antibody derivatives
such as diabody and intact antibody derivatives of D25 and D34
could be studied further in an in vivo setting.
Our data also show that RGD-helix structures with very long
helices retain excellent avb6-specificity and function-blocking
activity. Thus D25p has an a-helix almost 3-fold longer than the
parental peptide A20FMDV2. Interestingly, the D25p was a more
efficient inhibitor of avb6-cellular function than D34p which has a
shorter a-helix, whereas there was no difference in binding of
D34scFv versus D25scFv to cellular avb6 (Figure 3E). Thus, while
we have not established whether there is an optimal length of a-
helix for scFv specificity for avb6, we have established that
Figure 2. Screening of phage clones isolated from the a-helix & 310-helix libraries. A) Monoclonal scFv screening ELISA testing 96 clones in
each library. Bacterial supernatants were added to 5 mg/ml recombinant avb6 immobilized onto ELISA plate and then probed with mouse anti-Myc
antibody followed by anti-mouse-HRP. B) Clones with unique sequences were screened for binding cellular avb6 by flow cytometry. Figure shows
examples where scFv was tested at 100 (red histogram), 10 (orange histogram) and 1 (green histogram) mg/ml. For clarity the relevant avb6-specific
mouse monoclonal antibody 10D5 (grey) and the negative control IgG (black) histograms are also shown in each plot. C) Binding to cellular avb6 by
D25 and D34 verified by flow cytometry at 100 (red histogram), 10 (orange histogram) and 1 (green histogram) mg/ml. Size-exclusion
chromatography profile of purified of D25scFv and D34scFv showed a major peaks at 30 kDa.
doi:10.1371/journal.pone.0070452.g002
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relatively large 3D-motif-encoding sequences can be grafted into
CDR loops and result in function-blocking antibodies and VH-
CDR3 based peptides.
The concept introduced here can be adopted for other
therapeutic targets. Current studies have identified tumour
associated receptor tyrosine kinases that are being considered as
potential therapeutic targets [25–27] and it is likely that key
chemokine receptors [28] also will be similarly targeted. A similar
strategy to that described here, using the 3-dimensional shape of
the ligand-binding interface for these receptors, can generate
receptor-selective structurally-guided scFv, peptide or any other
protein scaffold libraries that would herald a new method for
creating valuable therapeutic antibodies. This approach has the
potential to replace the traditional approach whereby random
libraries are used to developed ligand antagonists and may result
in more powerful therapeutic antibodies.
Figure 3. Cellular avb6 binding efficacy of D25scFv, D34scFv, D25p and D34p. A) Binding to A375P b6 was demonstrated by flow
cytometry. The mean florescence intensity (MFI) values recorded from representative experiments are shown. A375Puro cells were used for the
negative control (puro) where none of the D25scFv or D34 scFvs (data not shown) or peptide derivatives (Figure S1) showed any binding. To avoid
repetition in the figure, the bar indicated as puro represent the binding of D25 scFv, D34 scFv which gave similar MFI when the primary scFv or
peptide were omitted as the binding to puro control cells (data not shown). B) Dose-dependent inhibition of the avb6 specific binding of A20FMDV2
(A20) was demonstrated with both D25 (D25scFv) and D34 (D34scFv). A20FMDV2 binding is expressed here as a percentage of the MFI value
detected in the absence of scFv. C) Dose-dependent inhibition of the avb6 specific binding of A20FMDV2 (A20) was demonstrated with D25p and
D34p peptides. A20FMDV2 binding is expressed here as a percentage of the MFI value detected in the absence of peptide inhibitors. D) avb6-
dependent adhesion to fibronectin was similarly inhibited by D25scFv and D34scFv (p.0.05). E) avb6-dependent adhesion to fibronectin was
inhibited by D25p and D34p. Significantly better inhibition of avb6-dependent adhesion to fibronectin was seen by D25p in comparison to D34p
(p = 0.0156).
doi:10.1371/journal.pone.0070452.g003
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Materials and Methods
Library construction and selection
Library construction is shown in Figure 7. A pool of 50 human
VH genes cloned into the pHEN1 vector was used as a PCR
template [5]. The library initially was amplified with LMB3
primer (Table 1), which anneals to pHEN1 vector sequences 59 to
the cloned VH gene and primer 1or 2, which anneals to 39 end of
the VH gene which was composed of the frame work 3 (FR3)
region, the structurally guided motifs encoded by the a- or 310 -
helix algorithms and finally the JH4 sequences (Table 1, Fig. 7A).
In a second PCR step, XhoI restriction site was introduced 39 to
the JH4 sequence after amplification with primer 1 or 2 and
LMB3 (Figure 7B). The VH gene amplicons containing inserts
encoding the algorithms were then digested with XhoI and NcoI
restriction enzymes and inserted into the NcoI and XhoI treated
pIT2 vector containing the VL repertoire (Fig. 7C, [3]).
The a-helix and 310 libraries were each rescued separately
KM13 helper phage as described previously [29]. For selection, we
used in parallel each library separately as well as mixed alpha helix
and 310 libraries. The initial phage selection was performed using
immobilised recombinant avb6 protein as described previously
[5,29] and http://www.lifesciences.sourcebioscience.com/
media/143421/tomlinsonij.pdf. After two rounds of selection on
immobilised avb6 we then selected the libraries on cell-expressed
avb6 using A375Pb6 and A375PPuro cell lines, for avb6-positive
and avb6-negative selection, respectively [14,22]. First line
screening were done by ELISA using 5 mg/ml immobilised
recombinant avb6 as described [29].
Cell lines
The adherent melanoma cell lines A375Pb6 and A375Ppuro,
described previously [22] were cultured in Dulbecco’s Modified
Eagles’ Medium (DMEM) supplemented with 10% Foetal Calf
Serum (FCS). The human oral squamous cell carcinoma VB6,
which was engineered to express high levels of avb6, was grown in
Keratinocyte Growth Medium as described [7].
Figure 4. Internalisation of D25scFv, D34scFv, D25p and D34p
in avb6-expressing cells. Internalisation of bound D25scFv (A,B) and
D34scFv (D, E) was assessed at 0 mins (A,D) and 45 mins (B,C,E,F) in
avb6-expressing cells (A,B,D,E) and detected using anti-myc antibody. In
control cells (C,F) only anti-myc antibody was used. The scFvs both were
internalised by avb6-expressing cells and some located to the nucleus.
The absence of nuclear staining with anti-myc antibody alone suggests
this was a true nuclear localisation. Internalisation of D25p (G, H, I) and
D34p (J, K, L) was assessed in avb6-expressing cells ((G,H,J,K) and avb6-
negative cells (I, L) at the times indicated. Both peptides were
internalised only by avb6-expressing cells. The scale bar shown
represents 20 mm.
doi:10.1371/journal.pone.0070452.g004
Figure 5. Localization of radiolabelled D25p in vivo. Single Photon Emission Computed Tomography imaging was used to localize the Indium-
111 radiolabelled D25p in vivo. The figure in the left panel represents a representative mouse at the one-hour time point, post injection. The three
images represent three different viewing angles – the sagittal (left), coronal (middle) and axial (right). Significantly more radioactivity was retained by
the avb6 positive tumour (indicated with solid arrow) compared with the avb6 negative tumour (indicated with the dashed arrow). Quantitative data
showing the average retention of radioactivity per gram of tumour in the three tested mice at the 1 h, 4 h and 24 h time points are shown in the
histogram. Significantly more radioactivity was retained by the avb6 positive tumour (p,0.01) compared with the avb6 negative tumour, and
significantly higher at 1 hr compare to 4 and 24 hr (p,0.01). No significant difference were seen in radioactivity retention in the avb6 negative
tumour between 1 hr and 4 and 24 hr in the (p.0.05).
doi:10.1371/journal.pone.0070452.g005
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Screening for integrin specificity by Flow Cytometry
Purified scFv were tested for specificity for avb6 by flow
cytometry using the isogenic pairs of cell lines, A375Pb6 and
A375Ppuro, or DX3b6 and DX3puro. Each pair expresses similar
levels of four RGD-binding integrins (avb3, avb5, avb8, a5b1) but
only A375Pb6 and DX3b6 express avb6 [14,22,30]. Briefly, cells
were detached with trypsin/EDTA, rinsed twice in ice-cold wash
buffer (0.1% BSA/DMEM/0.1% NaN3) and approximately
26105 cells re-suspended in 50 ml of wash buffer per sample. In
between all incubation steps, all samples were washed twice with
wash buffer unless otherwise stated. Cells were incubated on ice
for 1 hr with 0.1 or 1 uM purified scFv of peptide, washed twice.
For scFv, cells were then incubated for 1 hr on ice with mouse
anti-Myc antibody (clone 9E10, Santa Cruz) at 1:100. After
washing, bound antibody was detected with anti-mouse IgG-
Alexaflour 488 (1:250 for 1 h; Molecular Probes), on ice. Bound
VH-CDR3 derived peptide were detected by rabbit anti-biotin IgG
(1:200), followed by anti-rabbit IgG-Alexafluor 488 (1:250;
Molecular Probes). Cells were analysed using the FACSCalibur
(Beckton Dickinson). Cell expression of avb6 integrin was detected
with mouse monoclonal antibody (clone 10D5, 10 mg/ml;
Millipore) and non-specific (control) binding with non-immune
class matched IgG.
Inhibition of avb6 ligand binding
The scFv lead candidates propensity to inhibit binding of the
avb6-specific biotinylated-A20FMDV2 [19] to avb6-expressing
cells was determined by pre-incubation with purified scFv or
peptide (0.1 and 1.0 mM) for 10 mins, immediately followed by
40 mins incubation with the biotinylated A20FMDV2 (10 nM).
Figure 7. Cloning strategy used to build the scFv phage display libraries with synthetic structurally shaped VH-CDR3 containing the
a- and 310-helix. A. pHEN1 plasmid backbone containing scFv was used as the PCR template gene to be amplified with the primers LMB3 and the
Primer 1 or 2 that includes the FR3 sequences (yellow), flanked by the a- or 310-helix algorithms (red) and followed by JH4 sequences (brown). B. After
PCR amplification the resulted VH gene segment was rearranged with a- or 310-helix VH-CDR3 (red). To incorporate a unique Xho1 restriction site, the
PCR products derived from step A were amplified with LMB3 and Primer 3. C. The resultant PCR products from step B were digested with Nco1 and
Xho1 for insertion into the pIT2 plasmid backbone that contain light chain repertoire.
doi:10.1371/journal.pone.0070452.g007
Figure 6. NMR solution Structure of D25p and D34p. Figure
shows the 3D-rendering model for each peptide based on the mean of
20 NMR structures. Both peptides exhibited the RGD-helix motif. D34
which has 22 amino-acids has a shorter helix than peptide D25, which
has 29 amino-acids. Helices for both peptides were defined as standard
a-helix with the D34 a-helix running from Leu6-Leu17 and D25 a-helix
running from Leu6-Gln25.
doi:10.1371/journal.pone.0070452.g006
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Bound A20FMDV2 peptides were detected by rabbit anti-biotin
IgG (1:200), followed by anti-rabbit IgG-Alexafluor 488 (1:250;
Molecular Probes).
Fast protein liquid chromatography (FPLC)
The structural stability of scFv proteins was assessed by gel
filtration chromatography using a HiPrep 16/60 sephacryl S-200
(GE healthcare, Amersham, UK) connected to an AKTA FPLC
(GE healthcare, Amersham, UK). Fractionations were performed
in PBS at a flow rate of 0.3 ml/min with detection at 280 nm. A
Calibration Kit (GE healthcare, Amersham, UK) containing
protein markers (aprotinin, ribonuclease A, carbonic anhydrase,
ovalbumin and conalbumin) was used to generate a calibration
curve. Equal amounts of each of the protein markers were
prepared to 500 ml in PBS prior to loading onto the column. Kav
values derived from the equation: Kav = (Ve-V0)/(Vc-V0); where
Ve = elution volume, Vc = geometric column volume, and
V0 = column void volume were plotted against log molecular
weight to generate a protein calibration curve. Purified scFv
(50 ug/500 ul) was loaded onto the gel filtration column and
molecular weight of the different peaks was determined using the
calibration curve.
Internalisation Assay
In 24-well culture plates, 26104 cells avb6-positive and –
negative cells were seeded onto 13 mm diameter glass coverslips
and allowed to incubate overnight at 37uC in growth medium.
Cells were washed twice in serum free medium (SFM) and then
scFv (4 uM) or biotinylated-CDR3-peptide (100 nM) diluted in
SFM added on ice for 10 mins. After two ice-cold washes and a
further 109 on ice with mouse anti-biotin antibody (10 ug/ml) pre-
warmed media containing 10% FCS was added to the cells and
incubated at 37uC. At 10 min intervals between 0–60 mins, cells
were fixed in 2% HCHO in PBS and permeabilised with 0.1%
TritonX-100 (PBS) for 3 mins. scFv was detected with mouse anti
c-myc (1:100 dilution, clone 9E10; 309, ambient temperature)
while peptides were detected by rabbit anti-biotin IgG (1:200).
Both peptide and scFv detected with anti-mouse Alexa488 for 309.
Nuclei were counter-labelled with 49,6-diamidino-2-phenylindole
(DAPI), coverslips mounted with Mowiol and samples examined
by confocal microscopy (Zeiss LSM510, Welwyn Garden City).
Picogreen adhesion assay
All adhesion assays were performed in quadruplicate and
repeated at least 2–3 times. In a 96-well plate format, test wells
were coated with Fibronectin (10 ug/ml/PBS) and negative
control wells were coated with 0.1% BSA (bovine serum
albumin)/PBS. After incubation at 37uC for 1 hour, plates were
washed in PBS twice and blocked with 0.1% BSA/PBS for
30 mins at 37uC. Following a PBS rinse, cells were seeded into the
wells, the plate resting on ice to avoid dehydration and to ensure
an initial uniform temperature for the experiment. Purified scFv or
peptide was added (25 ul) to the wells at the desired concentra-
tions, before adding 1.56104 cells (25 ul) per well. In some
experiments, cells (1.56104) were pre-treated with b1 blocking
antibody AIIB2 at 10 ug/ml before seeding into test wells to block
the b1-dependent fibronectin adhesion. To determine percentage
adhesion, standard curves were generated by plating 0–2.56104
cells in separate wells. After incubating plates at 37uC for 309
plates were washed twice in 1 mM CaCl2/0.5 mM MgCl2/PBS
and transferred into 280uC for 15 mins. Adherent cells were
quantified using a Picogreen kit (Invitrogen) and analysed on a
fluorescence reader (FLUOstar Optima, BMG Labtech Ltd,
Bucks, UK).
In vivo localization
All animal procedures followed strict Home Office (UK)
guidelines under license number PPL 80/2279. Biotinylated-
peptide was radiolabelled with Indium-111. To 10 ug of DOTA-
Biotin (Macrocyclics.com #C-100) buffered in 1M Ammonium
Acetate (pH 5.5) was added Indium [111In]-acetate. The mixture
was heated to 80uC for 30 mins and cooled at RT for 10 mins.
The labelled DOTA-Biotin was added to streptavidin at a 1:1
Molar Ratio (1 mg of streptavidin per 17.6 ug of DOTA-Biotin).
To this mixture, 88 ug of botinylated-D25p was added and 10 ul
of the mixture analysed by size exclusion-HPLC to verify the
stability of radiolabelled products pre- and post-labelling (data not
shown). A total of 50MBq was used to label 25 ug of peptide; the
sample was divided into four such that each mouse received 12.5
MBq (6.25 ug) of 111In-labelled D25 peptide.
Female CD1 nu/nu athymic nude mice (Charles River) were
subcutaneously injected with 100 ml (26106 cells) of A373Pb6 into
the right shoulder and A375puro in the left shoulder. Tumours
were allowed to develop for 20 days and 200 ml of freshly
radiolabelled 111In-labelled D25 peptide was administered intra-
venously. Tumours were imaged by NanoSPECT/CT (Bioscan,
Inc) at 1 hr, 4 hr and 24 hr-time points as follows: Mice were
placed onto the imaging bed and initial low resolution CT scans
were collected at 45KVp, 180 projections per rotation, 500 ms per
projection. Subsequently SPECT images were acquired (45 min-
utes acquisition time) and data reconstructed using on-board
HiSPECT-NG software (Bioscan). To measure radioactivity
associated with tumours the NanoSPECT/CT machine was
calibrated (before the experiment) by imaging a phantom with
an Indium-111 standard solution. Subsequently Invivoscope
software (Invicro) was used to generate three-dimensional regions
of Interest (ROI) around the tumours and the ROIs converted to
megabequerels.
Table 1. Oligonucleotides used to build the structural guided library.
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Structural determination by NMR study
Solution NMR structures of peptides D25p and D34p on
0.1%TFE were solved as previously (13). All NMR data for
peptides A22 (D25p) and A29 (D34p) were obtained at 283 K
from a 14.1 T (600 MHz 1H) Bruker Avance III NMR
spectrometer equipped with a 5 mm QCI-F cryoprobe. All
NMR samples were 350 mL within a Shigemi NMR tube and
contained 1 mM peptide in 25 mM sodium phosphate buffer at
pH 6.5 also containing 50 mM sodium chloride, 4% (v/v)
dimethylsulfoxide (DMSO), and 30% (v/v) trifluroethanol-d3
(TFE). NMR data processing was completed using TopSpin 3.1
(Bruker), assignments were completed using CCPN Analysis.
1H chemical shifts and through-space structural assignments
were obtained from two-dimensional TOCSY and NOESY NMR
experiments with mixing times of 20 ms/60 ms for TOCSY and
250 ms for NOESY. The observed NOE contacts support the
presence of an a-helical conformation along the length of the
peptide with NOEs observed between Ha and HN (i–i+3) as well
as Ha and Hb (i–i+3). Structural ensembles were calculated using
CNS [31] and including dihedral angles confirmed by DANGLE
analysis [31] and predicted hydrogen-bond donor acceptor pairs.
The final ensemble was water-minimised using YASARA Struc-
ture software (available from http://www.yasara.org) and Rama-
chandran analysis of each peptide ensemble was completed using
PROCHECK-NMR [32].
Statistical analysis
The Wilcoxon matched-pairs signed rank test was used to
compare activity. Statistical analysis was performed using the
GraphPad Prism software package (GraphPad Software, San
Diego, CA).
Supporting Information
Figure S1 A375Ppuro cells were incubated with biotinylated
D25p or D34p at 1 uM. Bound peptide was detected with rabbit
anti-biotin IgG (1:200), followed by anti-rabbit IgG-Alexafluor 488
(1:250; Molecular Probes). Note that there was no significant
binding to the cells by either peptide (clear histograms). Black
histograms represent controls where peptides were omitted.
(TIF)
Figure S2 Structures of RGD peptides D34p (A+B) and
D25p (C+D) in 30% w/v TFE. RGD residues are shown as
sticks in A and C. Helices are drawn for and ensembles are fitted
to residues 6–17 and 6–25 for peptide D34p and D25p
respectively.
(TIF)
Figure S3 NOE contacts, chemical shift difference,
hydrogen bond donors and Dihedral restraints for
D34p peptide with 30% w/v TFE. The secondary structure
shown beneath the restraints indicates the limits of helix formation
according to Ramachandran analysis of the final 20 structure
ensemble.
(TIF)
Figure S4 NOE contacts, chemical shift difference,
hydrogen bond donors and Dihedral restraints for
D29p peptide in 30% w/v TFE. The secondary structure
shown beneath the restraints indicates the limits of helix formation
according to Ramachandran analysis of the final 20 structure
ensemble.
(TIF)
Table S1 NMR and refinement statistics for 20 struc-
ture ensembles of peptides.
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